Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 5/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14748198 | 1.00 | CA1 (0.38) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL27734627 | 0.86 | CA1 (0.35) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL6117658 | 0.84 | AAK1 (0.36) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL19176293 | 0.84 | CTSK (0.36) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL12326431 | 0.84 | CTSK (0.36) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL15672769 | 0.83 | CA1 (0.36) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL5154944 | 0.82 | CTSK (0.35) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL8738094 | 0.81 | ALDH1A1 (0.39) | CA1CA2CA7CA14CA12 | |
| SCHEMBL911189 | 0.81 | CA2 (0.36) | CA1CA2CA7CA14CA12 | |
| SCHEMBL13821846 | 0.81 | ALDH1A1 (0.39) | CA1CA2CA7CA14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557765-B2 | Spatially-defined macrocycles incorporating peptide bond surrogates | TRANZYME PHARMA INC. (CA) | 2013-10-15 | — | — | US | disclosed |
| US-20090312540-A1 | SPATIALLY-DEFINED MACROCYCLES INCORPORATING PEPTIDE BOND SURROGATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2009-12-17 | — | — | US | disclosed |
| US-7550431-B2 | Spatially-defined macrocycles incorporating peptide bond surrogates | TRANZYME PHARMA INC. (CA) | 2009-06-23 | — | — | US | disclosed |
| US-7550431-B2 | Spatially-defined macrocycles incorporating peptide bond surrogates | TRANZYME PHARMA INC. (CA) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312540-A1 | SPATIALLY-DEFINED MACROCYCLES INCORPORATING PEPTIDE BOND SURROGATES | MLNR, GIPR, GRPR | CA1 2385/4885CA2 3602/4885CA7 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.